Thus, in the current study, we examined (i) whether the presence of αSyn co-pathology as assessed via CSF-based SAAs promotes tau pathophysiology and aggregation in an AD context, and (ii) whether the putative αSyn-associated acceleration of tau aggregation contributes to faster cognitive decline. Here, PCSK1N is linked to Alzheimer disease.